- Home
- PTGX vs AMPH Comparison
PTGX vs AMPH Comparison
Compare PTGX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- AMPH
- Stock Information
- Founded
- PTGX 2006
- AMPH 1996
- Country
- PTGX United States
- AMPH United States
- Employees
- PTGX N/A
- AMPH N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- AMPH Health Care
- Exchange
- PTGX Nasdaq
- AMPH Nasdaq
- Market Cap
- PTGX 2.8B
- AMPH 2.5B
- IPO Year
- PTGX 2016
- AMPH 2014
- Fundamental
- Price
- PTGX $47.91
- AMPH $51.45
- Analyst Decision
- PTGX Strong Buy
- AMPH Buy
- Analyst Count
- PTGX 7
- AMPH 4
- Target Price
- PTGX $52.83
- AMPH $63.00
- AVG Volume (30 Days)
- PTGX 450.1K
- AMPH 268.7K
- Earning Date
- PTGX 11-08-2024
- AMPH 11-06-2024
- Dividend Yield
- PTGX N/A
- AMPH N/A
- EPS Growth
- PTGX N/A
- AMPH 62.07
- EPS
- PTGX 2.75
- AMPH 3.15
- Revenue
- PTGX $319,120,000.00
- AMPH $712,891,000.00
- Revenue This Year
- PTGX $400.33
- AMPH $18.04
- Revenue Next Year
- PTGX N/A
- AMPH $4.41
- P/E Ratio
- PTGX $17.54
- AMPH $16.26
- Revenue Growth
- PTGX 125.73
- AMPH 31.80
- 52 Week Low
- PTGX $13.76
- AMPH $36.56
- 52 Week High
- PTGX $48.89
- AMPH $65.92
- Technical
- Relative Strength Index (RSI)
- PTGX 60.40
- AMPH 59.40
- Support Level
- PTGX $45.33
- AMPH $49.38
- Resistance Level
- PTGX $48.89
- AMPH $51.84
- Average True Range (ATR)
- PTGX 1.28
- AMPH 1.25
- MACD
- PTGX 0.11
- AMPH 0.10
- Stochastic Oscillator
- PTGX 77.11
- AMPH 78.90
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.